Related posts
Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)COVID-19 Stocks to Save Your RRSP + Forecasts and Facts (Updated)Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 1 opinions in the last 12 months.
Experts are optimistic about the potential for Sanofi-Aventis (SNY-N) to break out and trade in a higher range following a drop in October 2023. The weak earnings and news of a spin-off of its consumer healthcare operations may have contributed to the stock touching the bottom of its range last year. However, experts believe that this drop was likely a one-off event. They would be surprised if the stock got back to the low-end of its range, barring any significant negative news or consistently weak earnings.
(A Top Pick Mar 12/20, Up 36%) The same idea as GSK. Hasn't done a whole lot. They are actually working on a Covid vaccine. In the meantime, non-covid visits have been decreased so there has been a hit on prescriptions. Once it comes back, they should do fine.
Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N
In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.
Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.
On 2024-11-15, Sanofi-Aventis (SNY-N) stock closed at a price of $47.97.
SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free